Advertisement

MMW - Fortschritte der Medizin

, Volume 161, Supplement 3, pp 52–60 | Cite as

Praxisnahe Tipps zu Diagnostik und Therapie

Chronisch entzündliche Darmerkrankungen

  • Thomas OchsenkühnEmail author
  • Daniel Szokodi
  • Cornelia Tillack
FORTBILDUNG . ÜBERSICHT
  • 284 Downloads

Zusammenfassung

Die Therapie der chronisch entzündlichen Darmerkrankungen (CED) Morbus Crohn (MC) und Colitis ulcerosa (CU) ist durch den Einsatz von Immunsuppressiva und Antikörpern zwar fundamental effektiver, aber auch anspruchsvoller geworden und daher heute fast ausschließlich in der Hand von CED-Spezialisten. Hausärzte spielen aber eine wichtige Rolle bei der Früherkennung der Erkrankung und der Begleitung der Patienten. Lesen Sie hier einen auf Leitlinien, Studien und Erfahrungswerten basierenden, pragmatischen Überblick über Diagnose und Therapie.

A short and pragmatic guide through diagnostics and therapies of chronic inflammatory bowel diseases

Keywords

Crohn’s disease ulcerative colitis guidelines diagnostics therapy 

Literatur

  1. 1.
    Colombel JF, Panaccione R, Bossuyt P et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2018;390:2779–89.PubMedCrossRefGoogle Scholar
  2. 2.
    Darfeuille-Michaud A, Boudeau J, Bulois P et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease. Gastroenterology. 2004;127:412–21.PubMedCrossRefGoogle Scholar
  3. 3.
    Tian Z, Liu J, Liao M et al. Beneficial effects of fecal microbiota transplantation on ulcerative colitis in mice. Dig Dis Sci. 2016;61:2262–71.PubMedCrossRefGoogle Scholar
  4. 4.
    Bennet JD, Brinkman M. Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet. 1989;1:164.PubMedCrossRefGoogle Scholar
  5. 5.
    Tao Zuo, Siew C. Ng. The gut microbiota in the pathogenesis and therapeutics of inflammatory bowel disease. Front Microbiol. 2018;9:2247.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Rosenstiel P, Sina C, Franke A, Schreiber S. Towards a molecular risk map—recent advances on the etiology of inflammatory bowel disease. Semin Immunol. 2009;21:334–5.PubMedCrossRefGoogle Scholar
  7. 7.
    Jostins L, Ripke S, Weersma RK et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119–24.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Frolkis A, Dieleman LA, Barkema HW et al. Environment and the inflammatory bowel diseases. Can J Gastroenterol. 2013;27:18–24.CrossRefGoogle Scholar
  9. 9.
    Molodecky NA, Soon IS, Rabi DM et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–54.PubMedCrossRefGoogle Scholar
  10. 10.
    Solberg IC, Lygren I, Jahnsen J et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009;44:431–40.PubMedCrossRefGoogle Scholar
  11. 11.
    Faubion WA, Jr, Loftus EV, Jr, Harmsen WS et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255–60.PubMedCrossRefGoogle Scholar
  12. 12.
    Michelassi F, Sultan S. Surgical treatment of complex small bowel Crohn disease. Ann Surg. 2014;260:230–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Henriksen M, Jahnsen J, Lygren I et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis. 2006;12:543–50.PubMedCrossRefGoogle Scholar
  14. 14.
    Preiß JC, Bokemeyer B, Buhr HJ et al. Aktualisierte S3-Leitlinie — „Diagnostik und Therapie des Morbus Crohn” 2014. Z Gastroenterol. 2014;52:1431–84.PubMedCrossRefGoogle Scholar
  15. 15.
    Kucharzik T, Dignass AU, Atreya Raja et al. Aktualisierte S3-Leitlinie Colitis ulcerosa der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). Z Gastroenterol. 2018;56:1087–1169.CrossRefGoogle Scholar
  16. 16.
    Gomollon F, Dignass A, Annese V et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management. Journal of Crohn’s and Colitis. 2017;11:3–25.PubMedCrossRefGoogle Scholar
  17. 17.
    Panes J, Bouzas R, Chaparro M et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn’s disease. Aliment Pharmacol Ther. 2011;34:125–45.PubMedCrossRefGoogle Scholar
  18. 18.
    Tillack C, Seiderer J, Brand S et al. Correlation of magnetic resonance enteroclysis (MRE) and wireless capsule endoscopy (CE) in the diagnosis of small bowel lesions in Crohn’s disease. Inflamm Bowel Dis. 2008;14:1219–28.PubMedCrossRefGoogle Scholar
  19. 19.
    Romkens TE, Kampschreur MT, Drenth JP et al. High mucosal healing rates in 5-ASA-treated ulcerative colitis patients: results of a meta-analysis of clinical trials. Inflamm Bowel Dis. 2012;18:2190–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Wang Y, Parker CE, Bhanji T et al. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016;4:CD000543.PubMedGoogle Scholar
  21. 21.
    Lichtiger S, Present DH, Kornbluth A et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330:1841–5.PubMedCrossRefGoogle Scholar
  22. 22.
    Williams JG, Alam MF, Alrubaiy L et al. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial. Lancet Gastroenterol Hepatol. 2016;1:15–24.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Danese S, Fiorino G, Peyrin-Biroulet L et al. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med. 2014;20:160:704–11.Google Scholar
  24. 24.
    Feagan BG, Rutgeerts P, Sands BE et al.: Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699–710.PubMedCrossRefGoogle Scholar
  25. 25.
    Kotlyar DS, Lewis JD, Beaugerie L et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol. 2015;13:847–58.PubMedCrossRefGoogle Scholar
  26. 26.
    Beigel F, Steinborn A, Schnitzler F et al. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies. Pharmacoepidemiol Drug Saf. 2014;23:735–44.PubMedCrossRefGoogle Scholar
  27. 27.
    Qiu Y, Mao R, Chen BL et al. Effects of combination therapy with immunomodulators on trough levels and antibodies against TNF antagonists in patients with Inflammatory Bowel Disease: A Meta-analysis. Clin Gastroenterol Hepatol. 2017;15:1359–72.PubMedCrossRefGoogle Scholar
  28. 28.
    Jeong DY, Kim S, Son MJ et al. Induction and maintenance treatment of inflammatory bowel disease: A comprehensive review. Autoimmun Rev. 2019;18:439–54.PubMedCrossRefGoogle Scholar
  29. 29.
    Sandborn WJ et al. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2017;376:1723–36.CrossRefGoogle Scholar
  30. 30.
    Aschenbrenner D. Tofacitinib trial prompts FDA review of adverse effects. American Journal of Nursing. 2019:119:25.PubMedCrossRefGoogle Scholar
  31. 31.
    Sands BE, Han C, Zhang Het al. P681 Ustekinumab therapy induced clinically meaningful improvement and remission as measured by the Inflammatory Bowel Disease Questionnaire: Results from the phase 3 UNIFI induction and maintenance studies. ECCO abstract P681; 2019.Google Scholar
  32. 32.
    Ochsenkühn T, Tillack C, Szokodi D et al. One-year experience with ustekinumab in therapy-refractory or -intolerant patients with ulcerative colitis. Journal of Crohn’s and Colitis. 2019;13:298–9.CrossRefGoogle Scholar
  33. 33.
    Lunney PC, Kariyawasam VC, Wang RR et al. Smoking prevalence and its influence on disease course and surgery in Crohn’s disease and ulcerative colitis. Alimentary Pharmacology and Therapeutics. 2015;42:61–70.PubMedCrossRefGoogle Scholar
  34. 34.
    Hanauer SB, Sandborn WJ, Feagan BG et al. IM-UNITI: 3 year efficacy, safety, and immunogenicity of ustekinumab treatment of Crohn’s disease. J Crohns Colitis. 2019; pii: jjz110. doi:  https://doi.org/10.1093/ecco-jcc/jjz110. [Epub ahead of print]
  35. 35.
    Mantzaris GJ. Thiopurines and methotrexate use in IBD patients in a biologic era. Curr Treat Options Gastroenterol 2017;15:84–104.PubMedCrossRefGoogle Scholar
  36. 36.
    Jørgensen KK, Olsen IC, Goll GL et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389:2304–16.PubMedCrossRefGoogle Scholar
  37. 37.
    Ye BD, Pesegova M, Alexeeva O et al. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn’s disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet. 2019;393:1699–1707.PubMedCrossRefGoogle Scholar
  38. 38.
    Gecse KB, Végh Z, Lakatos PL. Optimizing biological therapy in Crohn’s disease. Expert Rev Gastroenterol Hepatol. 2016;10:37–45.PubMedCrossRefGoogle Scholar
  39. 39.
    Allen PB, Olivera P, Emery P et al. Review article: moving towards common therapeutic goals in Crohn’s disease and rheumatoid arthritis. Aliment Pharmacol Ther. 2017;45:1058–72.PubMedCrossRefGoogle Scholar
  40. 40.
    Parragi L, Fournier N, Zeitz J et al. Colectomy Rates in Ulcerative Colitis are Low and Decreasing: 10-year Follow-up Data From the Swiss IBD Cohort Study. J Crohns Colitis 2018;12:811–18.PubMedCrossRefGoogle Scholar
  41. 41.
    Jürgens M, Laubender RP, Hartl F et al. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am J Gastroenterol. 2010;105:1811–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Braun I, Heitland W, Bader F et al. Einfluss des präoperativen Einsatzes von TNF-alpha-Antikörpern auf den peri- und postoperativen Verlauf von CED-Patienten mit Darmresektionen. Z Gastroenterol. 2018;56:e215–6.Google Scholar
  43. 43.
    Lightner AL, McKenna NP, Alsughayer A et al. Anti-TNF biologic therapy does not increase postoperative morbidity in pediatric Crohn’s patients. Pediatr Surg. 2019; S0022-3468(19)30015-6. doi:  https://doi.org/10.1016/j.jpedsurg.2019.01.006. [Epub ahead of print].PubMedCrossRefGoogle Scholar
  44. 44.
    Xu Y, Yang L, An P et al. Meta-Analysis: The influence of preoperative infliximab use on postoperative complications of Crohn’s Disease. Inflamm Bowel Dis. 2019;25:261–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Brennan GT, Ha I, Hogan C et al. Does preoperative enteral or parenteral nutrition reduce postoperative complications in Crohn’s disease patients: a meta-analysis. Eur J Gastroenterol Hepatol. 2018;30:997–1002.PubMedCrossRefGoogle Scholar
  46. 46.
    Lichtiger S, Present DH. Preliminary report: Cyclosporin in treatment of severe active ulcerative colitis. Lancet;1990;226:16–9.CrossRefGoogle Scholar
  47. 47.
    Herrmann KA, Michaely HJ, Seiderer J, Ochsenkuehn T et al. The „star-sign“ in magnetic resonance enteroclysis: a characteristic finding of internal fistulae in Crohn’s disease. Scand J Gastroenterol. 2006;41:239–41.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  • Thomas Ochsenkühn
    • 1
    Email author
  • Daniel Szokodi
    • 1
  • Cornelia Tillack
    • 1
  1. 1.Crohn- und Colitis-Zentrum MünchenMünchenDeutschland

Personalised recommendations